Compare Microchip Technology Inc. (MCHP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs TG Therapeutics Inc — how do they compare? Microchip Technology Inc. trades at $75.72 (market cap $41.01B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Microchip Technology Inc. is far larger — about 5× TG Therapeutics Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and TG Therapeutics Inc for 16 Days on average.
| MCHP | TGTX | |
|---|---|---|
Market Cap | $41.01B | $8.16B |
Volume | 9,972,516 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $102.97 | $59.06 |
52-Week Low | $49.02 | $26.94 |
Typical Hold Time | 63 Days | 16 Days |
Enterprise Value | $46.13B | $8.37B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $75.55, down 3.17% over the past day, with a bearish technical signal from moving averages. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, though revenue declined to $4.40B. Analyst consensus is strongly bullish with a $110.50 price target, and recent news highlights expansion in Ethernet and 48V power portfolios alongside the acquisition of Hailo to bolster edge AI capabilities.
MCHP faces near-term headwinds from profitability pressures and high debt, but long-term growth is supported by AI infrastructure demand and strategic expansions. Investment opportunities exist if operational improvements and market trends materialize, though risks include competitive intensity and execution challenges in a cyclical semiconductor market.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
